Blog

Cue Biopharma in $374M-plus Merck immunotherapy pact – FierceBiotech


FierceBiotech

Cue Biopharma in $374M-plus Merck immunotherapy pact
FierceBiotech
After raising $26 million at the start of the year, cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck. Financial details are patchy, but we know the Big Pharma could pay up to $374 million
Cue Biopharma Announces Strategic Research Collaboration and License Agreement with MerckBusiness Wire (press release)



all 2 news articles »

2017-11-16 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.